Shukra Pharmaceuticals, a fast emerging player in India’s medical devices sector, has committed ₹587 crore to build a large-scale manufacturing plant in Uttar Pradesh, reinforcing the state’s ambition to emerge as a major hub for medtech production. The investment was formally declared on January 24, 2026, following detailed discussions with the Uttar Pradesh Industrial Development Authority (UPIEDA) and the state’s Department of Medical, Health and Family Welfare.

The proposed facility will be located in the rapidly developing Jewar Bulandshahr industrial corridor, benefiting from proximity to the upcoming Noida International Airport, the Yamuna Expressway, and major logistics hubs. Spread across roughly 50 acres, the plant will feature Class 100,000 and Class 10,000 cleanrooms, fully automated injection moulding and assembly lines, dedicated R&D and prototyping centres, and in-house validation labs to meet stringent international quality requirements.

The product portfolio will span high-demand categories including disposable surgical consumables (syringes, IV sets, catheters, surgical drapes), precision orthopaedic implants, diagnostic disposables (blood collection tubes, rapid test kits), and select minimally invasive surgical instruments. The facility is designed with scalability in mind, with initial capacity targeting 500–700 million units annually and built-in flexibility for future expansion into biologics packaging and advanced wound care products.

The Uttar Pradesh government has extended significant incentives under its Industrial Investment & Employment Promotion Policy, including land at subsidised rates, capital subsidy of up to 25%, stamp duty exemptions, electricity duty waivers for 10 years, and SGST reimbursement for seven years. Shukra has committed to creating over 2,500 direct jobs (engineers, technicians, quality professionals, and support staff) and thousands more indirectly through local vendor development and logistics.

Amit Shukla, Founder & Managing Director of Shukra Pharmaceuticals, said: “Uttar Pradesh offers the perfect combination of policy support, land availability, skilled manpower, and strategic location. This facility will not only meet surging domestic demand for quality medical devices but also enable us to compete aggressively in global export markets while contributing to India’s self reliance in critical healthcare products.”

The project aligns with the national Production Linked Incentive (PLI) scheme for medical devices and the state’s broader industrialisation drive. It is expected to reduce India’s reliance on imported consumables and devices, lower healthcare costs, and generate substantial export revenue as Shukra targets markets in Africa, Southeast Asia, and Latin America.

Site preparation and regulatory clearances are already underway, with groundbreaking anticipated in mid-2026 and phased commercial production starting by late 2027. The facility is designed to achieve full US FDA and CE compliance from day one, positioning Shukra as a reliable global supplier.